Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT

EBV-associated post-transplant lymphoproliferative disease (PTLD) remains an important complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT). We retrospectively analysed the incidence and risk factors for EBV reactivation in 186 adult patients undergoing consecutive allo-HS...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Bone Marrow Transplant
Auteurs principaux: Burns, D M, Rana, S, Martin, E, Nagra, S, Ward, J, Osman, H, Bell, A I, Moss, P, Russell, N H, Craddock, C F, Fox, C P, Chaganti, S
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2016
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4880046/
https://ncbi.nlm.nih.gov/pubmed/26901708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2016.19
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires